Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis

Journal of Rheumatology

Volumn 41, Issue 11, 2014, Pages 2290-2294

  Orbai, Ana Maria ^a   Weitz, Joshua ^b   Siegel, Evan L ^c   Siebert, Stefan ^d   Savage, Laura J ^e   Aydin, Sibel Z ^f   Luime, Jolanda J ^g   Elkayam, Ori ^h   Neerinckx, Barbara ⁱ   Urbancek, Slavo ^j   De Vlam, Kurt ⁱ   Ritchlin, Christopher T ^k  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Dermatology Associates of Rochester   (United States)

^c Arthritis and Rheumatism Brach   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f KOÇ UNIVERSITY   (Turkey)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j Fakultna nemocnica s poliklinikou FD Roosevelta Banska Bystrica   (Slovakia)

^k UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

Enthesitis; Enthesopathy psoriatic arthritis; Outcome measures; Treatment

Indexed keywords

ADALIMUMAB; APREMILAST; CERTOLIZUMAB PEGOL; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; PLACEBO; SALAZOSULFAPYRIDINE; USTEKINUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

EFFECT SIZE; ENTHESITIS; HEALING IMPAIRMENT; HUMAN; IMPACT INDEX; LEEDS ENTHESITIS INDEX; MAASTRICHT ANKYLOSING SPONDYLITIS ENTHESITIS SCORE; MODIFIED MANDER ENTHESITIS INDEX; MUSCULOSKELETAL DISEASE ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS MODIFIED MAASTRICHT ANKYLOSING SPONDYLITIS ENTHESITIS SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TENDINITIS; ARTHRITIS, PSORIATIC; DRUG EFFECTS; FEMALE; JOINT CAPSULE; LIGAMENT; MALE; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RHEUMATIC DISEASES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STANDARDS; TENDINOPATHY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; JOINT CAPSULE; LIGAMENTS, ARTICULAR; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHEUMATIC DISEASES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; TENDINOPATHY; TREATMENT OUTCOME;

EID: 84923260755     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140878     Document Type: Review

References (28)

1. Sakkas LI, Alexiou I, Simopoulou T., Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum 2013; 43:325-34.
2. Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005; 17:406-12.
3. Aydin SZ, Ash ZR, Tinazzi I, Castillo-Gallego C, Kwok C., Wilson C, et al. The link between enthesitis and arthritis in psoriatic arthritis: A switch to a vascular phenotype at insertions may play a role in arthritis development. Ann Rheum Dis 2013; 72:992-5.
4. Smolen JS, Braun J, Dougados M., Emery P, Fitzgerald O, Helliwell P., et al. Treating Spondylarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: Recommendations of an international task force. Ann Rheum Dis 2014; 73:6-16.
5. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008; 59:686-91.
6. Coates LC, Ritchlin CT, Kavanaugh AF. GRAPPA treatment recommendations: An update from the GRAPPA 2013 Annual Meeting. J Rheumatol 2014; 41:1237-9.
7. Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL). J Rheumatol Suppl 2012; 89:90-3.
8. Antoni CE, Kavanaugh A, Kirkham B., Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologie and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005; 52:1227-36.
9. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A., Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150-7.
10. Mease PJ, Gladman DD, Ritchlin C.T., Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:3279-89.
11. Genovese MC, Mease PJ, Thomson G.T., Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34:1040-50.
12. Kavanaugh A, Mclnnes I, Mease P., Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976-86.
13. Gottlieb A, Menter A, Mendelsohn A., Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633-40.
14. Sterry W, Ortonne JP, Kirkham B, Brocq O., Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340:c147.
15. Clegg DO, Reda DJ, Mejias E, Cannon G.W., Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2013-20.
16. Mclnnes IB, Kavanaugh A, Gottlieb A.B., Puig L., Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780-9.
17. Mease PJ, Fleischmann R, Deodhar A.A., Wollenhaupt J., Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73:48-55.
18. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo A.O., Wollenhaupt J., Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73:1020-6.
19. Ritchlin C, Rahman P, Kavanaugh A., Mclnnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73:990-9.
20. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
21. Mease PJ, Goffe BS, Metz J, VanderStoep A., Finck B, Bürge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356:385-90.
22. Dean BJ, Lostis E, Oakley T., Rombach I, Morrey ME, Carr AJ. The risks and benefits of glucocorticoid treatment for tendinopathy: A systematic review of the effects of local glucocorticoid on tendon. Semin Arthritis Rheum 2014; 43:570-6.
23. Cohen J. A power primer. Psychol Bull 1992; 112:155-9.
24. Gladman DD, Inman RD, Cook R.J., Maksymowych WP, Braun J, Davis JC, et al. International Spondylarthritis interobserver reliability exercise-the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007; 34:1740-5.
25. Clegg DO, Reda DJ, Weisman M.H., Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2004-12
26. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987; 46:197-202.
27. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van ver Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62:127-32.
28. Ibrahim G, Groves C, Chandramohan M., Beltran A, Valle R, Reyes B., et al. Clinical and ultrasound examination of the Leeds Enthesitis Index in psoriatic arthritis and rheumatoid arthritis. ISRN Rheumatol 2011:731917.